OGN

Handel nachbörslich: 9.70 0.02 +0.21%

Organon Co (OGN)

Überblick Nachrichten Preisverlauf Optionskette Financials Forum Prognose Dividendenhistorie

Schlusskurs vom Vortag:

24-Stunden-Volumen:

Relative Volume:

Marktkapitalisierung:

Nettoeinkommen (Verlust:

Netto-Cashflow:

1W Leistung:

1M Leistung:

6M Leistung:

1J Leistung:

1-Tages-Spanne:

1-Wochen-Bereich:

52-Wochen-Spanne:

Organon Co Stock (OGN) Company Profile

Healthcare (1151)

551-430-6000

30 HUDSON STREET, JERSEY CITY

Nächster Verdiensttermin

Neueste SEC-Einreichungen

OGN's Discussions on Twitter

Vergleichen Sie OGN mit anderen Aktien

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
OGN Organon Co	9.68	2.45B	6.29B	750.00M	586.00M	2.88
LLY Lilly Eli Co	742.91	659.07B	53.26B	13.80B	-50.20M	15.30
JNJ Johnson Johnson	178.76	428.83B	90.62B	22.66B	18.18B	9.35
ABBV Abbvie Inc	213.00	374.37B	58.33B	3.73B	18.24B	2.10
NVS Novartis Ag Adr	128.42	245.16B	53.40B	13.68B	16.89B	6.9231
MRK Merck Co Inc	84.05	213.51B	63.43B	16.42B	14.72B	6.49

Organon Co Stock (OGN) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2025-05-02	Herabstufung	Evercore ISI	Outperform → In-line
2024-09-06	Herabstufung	JP Morgan	Neutral → Underweight
2023-11-03	Herabstufung	Goldman	Buy → Neutral
2023-09-21	Eingeleitet	Barclays	Overweight
2023-03-16	Eingeleitet	Raymond James	Outperform
2022-10-14	Herabstufung	BofA Securities	Neutral → Underperform
2022-09-06	Hochstufung	Piper Sandler	Neutral → Overweight
2022-08-05	Herabstufung	BofA Securities	Buy → Neutral
2022-04-27	Eingeleitet	Goldman	Buy
2022-04-06	Fortgesetzt	Morgan Stanley	Equal-Weight
2021-10-07	Eingeleitet	Piper Sandler	Neutral
2021-09-01	Eingeleitet	BofA Securities	Buy
2021-07-22	Eingeleitet	Citigroup	Buy
2021-06-15	Eingeleitet	JP Morgan	Neutral
2021-06-11	Eingeleitet	Morgan Stanley	Equal-Weight
2021-06-10	Eingeleitet	Evercore ISI	Outperform

Alle ansehen

Organon Co Aktie (OGN) Neueste Nachrichten

Finanzdaten der Organon Co-Aktie (OGN)

Organon Co (OGN)

Organon Co Stock (OGN) Company Profile

Vergleichen Sie OGN mit anderen Aktien

Organon Co Stock (OGN) Upgrades & Downgrades

Organon Co Aktie (OGN) Neueste Nachrichten

Organon And Henlius Are Latest To Receive Denosumab Nod In US - insights.citeline.com

Organon and Henlius get FDA nod for Amgen biosimilars (OGN) - Seeking Alpha

Major Breakthrough: FDA Approves Two New Biosimilars to Treat Millions with Bone Health Conditions - Stock Titan

Organon's Upside Potential: Can Biosimilars and Women’s Health Drive a Re-rating? - AInvest

Will Raised Revenue Guidance and New Launches Shift Organon's (OGN) Growth Outlook? - simplywall.st

How Investors Are Reacting To Organon (OGN) Lifting 2025 Guidance and CEO Share Purchase - Yahoo Finance

Organon & Co. (OGN) Advances VTAMA Cream, Strengthens Women’s Health Portfolio - MSN

Organon & Co. (OGN) Is a Trending Stock: Facts to Know Before Betting on It - Yahoo Finance

Organon & Co. (OGN) is Attracting Investor Attention: Here is What You Should Know - MSN

Organon & Co. shares rise 1.57% intraday after Trane Technologies launches Season 5 of Healthy Spaces podcast. - AInvest

Organon & Co. shares fall 1.02% intraday after Genentech files BPCIA complaint against Organon and Henlius. - AInvest

Henlius And Organon Sued In US Over Plans To Market Perjeta Biosimilar - insights.citeline.com

Does Organon's Raised 2025 Guidance Signal a Turning Point for OGN Investors? - simplywall.st

Kahn Brothers' Q2 2025 13F Filing: Alphabet, Comcast, and Organon Highlights - AInvest

Organon in charts: Women's Health revenue up ~3% Y/Y in Q2 - MSN

Roche Sues Organon in First Case Over Biosimilar Copy of Perjeta - Bloomberg Law News

There May Be Some Bright Spots In Organon's (NYSE:OGN) Earnings - Yahoo Finance

Organon & Co. (OGN) Stock Price, News & Analysis - MarketBeat

Daré Bioscience Posts Narrower Q2 Loss - The Motley Fool

OGN’s Market Whiplash: -52.64% YTD Decline, -4.30% Plunge in 30 Days - investchronicle.com

Bullish Organon Insiders Loaded Up On US$651.6k Of Stock - 富途牛牛

Organon & Co.'s Q2 2025 Earnings Call: Unraveling Key Contradictions in Capital Allocation, Nexplanon Growth, and Financial Forecasts - AInvest

LPL Financial LLC Has $4.87 Million Holdings in Organon & Co. (NYSE:OGN) - Defense World

NYSE: OGN Lawsuit Alert: Investors who lost money with Organon & Co. (NYSE: OGN) shares should contact the Shareholders Foundation - The Malaysian Reserve

Ex-Dividend Reminder: Cencora, Organon and Esquire Financial Holdings - Nasdaq

5 Must-Read Analyst Questions From Organon’s Q2 Earnings Call - Yahoo Finance

OGN Q2 Deep Dive: Flat Sales, Margin Pressure, and Strategic Shifts Highlight Quarter - Yahoo Finance

Organon's Valuation: Discounted Due to Structural Challenges - AInvest

Organon: Valuation Discount Offset By Structural Headwinds (NYSE:OGN) - Seeking Alpha

Investors Heavily Search Organon & Co. (OGN): Here is What You Need to Know - MSN

Natixis Advisors LLC Has $778,000 Holdings in Organon & Co. (NYSE:OGN) - Defense World

Organon & Co. (OGN): Assessing Dividend Sustainability and Valuation Amid Earnings Pressures and Strategic Catalysts - AInvest

Read This Before Considering Organon & Co. (NYSE:OGN) For Its Upcoming US$0.02 Dividend - uk.finance.yahoo.com

Organon & Co. (OGN) Reports Q2 2025 Results - MSN

Organon Q2 Preview: What to expect? - MSN

Organon & Co. (NYSE:OGN) Given Average Recommendation of “Moderate Buy” by Brokerages - Defense World

Organon & Co. Reports Q2 2025 Earnings, Raises Full-Year Guidance - AInvest

Organon & Co. (NYSE:OGN) Second-Quarter Results: Here's What Analysts Are Forecasting For This Year - Yahoo Finance

Organon & Co. Reports Q2 2025 Financial Results - The Globe and Mail

Organon & Co. Earnings Call: Resilience Amid Challenges - The Globe and Mail

Organon (OGN) Fiscal Q2 Revenue Beats 1% - AOL.com

Organon & Co. (OGN) Slashes 13.13% on Disappointing Earnings - MSN

Organon Q2 Earnings: It May Be Time To Desert This Sinking Ship (Downgrade) (NYSE:OGN) - Seeking Alpha

Endometriosis Pipeline 2025: Key Companies, MOA, ROA, and Clinical Trials Evaluation by DelveInsight | Organon, Ironwood Pharma, Mitsubishi Tanabe Pharma Corp, AbbVie/Neurocrine Biosciences - The Globe and Mail

Organon & Co. SEC 10-Q Report - TradingView

Organon & Co. (NYSE:OGN) Q2 2025 Earnings Call Transcript - Insider Monkey

Organon jumps despite Q2 revenue dip as revised outlook exceeds consensus - MSN

Organon Reports Results for the Second Quarter Ended June 30, 2025 - BioSpace

ORGANON SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Organon & Co.OGN - Discover 361

Organon & Co (OGN) Q2 2025 Earnings Call Highlights: Navigating Challenges with Strategic Growth By GuruFocus - Investing.com Canada

Finanzdaten der Organon Co-Aktie (OGN)

Umsatz

Nettogewinn

Free Cashflow

ENV

Ähnlich wie OGN